A phase Ib study of anlotinib plus TQB2450 as second-line therapy for advanced biliary tract adenocarcinoma. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This abstract does ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results